CalciMedica

📍 La Jolla, United States🗓 Founded 2007👥 10 employees💰 Last funded Jun 2013
Biotechnology🌐 calcimedica.com
Website LinkedIn
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2007
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in CalciMedica?
CalciMedica has 1 investors on record on gritt.io and 1 late-stage investors.
When did CalciMedica last raise funding?
The most recent investment in CalciMedica recorded on gritt.io was in June 2013.
When was CalciMedica founded?
CalciMedica was founded in 2007.
What industry is CalciMedica in?
CalciMedica operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is CalciMedica based?
CalciMedica is headquartered in La Jolla, United States.